At Novoviah Pharmaceuticals, we are committed to advancing the identification and care of patients with chronic immune and digestive diseases by harnessing the patient-clinician experience to discover and develop novel diagnostics and therapeutics. Our diagnostics program aims to enhance patient care and support pharmaceutical development in celiac disease and other antigen-driven conditions by providing unique, ultrasensitive blood tests measuring rare antigen-specific T cells. Our exploratory gastrointestinal therapeutics program utilizing repurposed and novel drug candidates is guided by clinical insights implicating gut luminal anions as unrecognized but important drivers of symptoms in a wide range of digestive diseases. Arising from our Founder’s 20+ years’ experience researching and studying celiac disease and inflammatory bowel diseases, Novoviah Pharmaceuticals’ break-through foundation product is the ultra-sensitive Novoleukin immuno-diagnostic platform.